← Browse by Condition
Medical Condition
obesity and overweight
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2
Obesity research has been transformed by the GLP-1 receptor agonist class (semaglutide, tirzepatide), which achieves 15–22% body weight reduction — approaching surgical outcomes — and reduces cardiovascular events in overweight adults. The pipeline now includes amylin analogs, glucose-dependent insulinotropic polypeptide (GIP) agonists, and oral small molecules targeting appetite regulation.
Active trials investigate next-generation GLP-1 combinations, bimagrumab (anti-ActRII for muscle-sparing weight loss), retatrutide, cagrilintide combinations, and gut microbiome modulators. Trials also study weight regain prevention after GLP-1 discontinuation — an emerging clinical challenge.
Obesity trials typically require a BMI ≥30 or ≥27 with weight-related comorbidities; prior bariatric surgery often excludes participants.
Frequently Asked Questions — obesity and overweight Clinical Trials
How many clinical trials are currently recruiting for obesity and overweight?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for obesity and overweight, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for obesity and overweight?
obesity and overweight research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a obesity and overweight clinical trial?
Eligibility criteria for obesity and overweight trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06623669 Phase 2
Recruiting
A Mobile Intervention to Reduce Pain and Improve Health-III
Enrollment
200 pts
Location
United States
Sponsor
Wake Forest University
NCT06949280
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Enrollment
44 pts
Location
United States
Sponsor
Rutgers, The State University ...
NCT06935838 Phase 2
Recruiting
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
Enrollment
12 pts
Location
United States
Sponsor
University of Hawaii
NCT06935513
Recruiting
Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations
Enrollment
300 pts
Location
China
Sponsor
Affiliated Hospital of Nantong...
NCT06724406
Recruiting
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
Enrollment
256 pts
Location
United States
Sponsor
University of North Carolina, ...
NCT07043166
Recruiting
Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
Enrollment
4,094 pts
Location
China
Sponsor
Shanghai Changzheng Hospital
NCT07255274
Recruiting
Overweight and Obesity in Adolescents - Sleep Behavioral Intervention
Enrollment
126 pts
Location
Portugal
Sponsor
University of Beira Interior
NCT06734312
Recruiting
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
Enrollment
20 pts
Location
United States
Sponsor
Dr. Christopher McGowan
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology